Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2V617F mutation
| dc.rights.license | open | en_US |
| hal.structure.identifier | CHU Bordeaux | |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | GUY, Alexandre | |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | HELZY, Khalil | |
| hal.structure.identifier | CHU Bordeaux | |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | MANSIER, Olivier | |
| hal.structure.identifier | Hôpital Louis Pradel [CHU - HCL] | |
| dc.contributor.author | BORDET, Jean-Claude | |
| hal.structure.identifier | Service de médecine interne et maladies infectieuses [Bordeaux] | |
| hal.structure.identifier | Hôpital Haut-Lévêque [CHU Bordeaux] | |
| dc.contributor.author | RIVIERE, Etienne | |
| hal.structure.identifier | CHU Bordeaux | |
| dc.contributor.author | FIORE, Mathieu | |
| hal.structure.identifier | CHU Bordeaux | |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | JAMES, Chloé | |
| dc.date.accessioned | 2023-03-10T08:53:59Z | |
| dc.date.available | 2023-03-10T08:53:59Z | |
| dc.date.issued | 2023-02 | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/172245 | |
| dc.description.abstractEn | Background: JAK2V617F and Calreticulin (CALR) mutations are the most frequent molecular causes of Phi-negative myeloproliferative neoplasms (MPN). Patients with CALR mutations are at lower risk of thrombosis than patients with JAK2V617F. We hypothesized that CALR-mutated blood platelets would have platelet function defects that might explain why these patients are at lower risk of thrombosis. Objectives: Our main objective was to explore and compare platelet function depending on the MPN molecular marker. Methods: We analyzed platelet function in 16 patients with MPN with CALR mutations and 17 patients with JAK2V617F mutation and compared them with healthy controls. None of these patients was taking antiplatelet therapy. We performed an extensive analysis of platelet function and measured plasmatic soluble P-selectin and CD40L levels. Results: We observed significant defects in platelet aggregation, surface glycoprotein expression, fibrinogen binding, and granule content in platelets from patients with MPN compared with that in controls. Moreover, soluble CD40L and P-selectin levels were elevated in patients with MPN compared with that in controls, suggesting an in vivo platelet preactivation. Comparison of platelet function between patients with CALR and JAK2V617F MPN revealed only minor differences in platelets from patients with CALR. However, these results need to be interpreted within the context of absence of an inflammatory environment that could impact platelet function during MPN. Conclusions: These results do not support the hypothesis that calreticulin-mutated platelets have platelet function defects that could explain the lower thrombotic risk of patients with CALR. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject | Article clinique | |
| dc.subject.en | blood platelets | |
| dc.subject.en | calreticulin | |
| dc.subject.en | JAK2V617F mutation | |
| dc.subject.en | myeloproliferative neoplasms | |
| dc.subject.en | platelet aggregation | |
| dc.subject.en | thrombosis | |
| dc.title.en | Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2V617F mutation | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.rpth.2023.100060 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Médecine humaine et pathologie | en_US |
| bordeaux.journal | Research and Practice in Thrombosis and Haemostasis | en_US |
| bordeaux.page | 100060 | en_US |
| bordeaux.volume | Vol. 7 | en_US |
| bordeaux.hal.laboratories | Biologie des maladies cardiovasculaires (BMC) - UMR 1034 | en_US |
| bordeaux.issue | Issue 2 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04274001 | |
| hal.version | 2 | |
| hal.date.transferred | 2023-11-10T03:37:15Z | |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | CC BY | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Research%20and%20Practice%20in%20Thrombosis%20and%20Haemostasis&rft.date=2023-02&rft.volume=Vol.%207&rft.issue=Issue%202&rft.spage=100060&rft.epage=100060&rft.au=GUY,%20Alexandre&HELZY,%20Khalil&MANSIER,%20Olivier&BORDET,%20Jean-Claude&RIVIERE,%20Etienne&rft.genre=article |
